Top 12 Generic Drug Approval Winners in China | H1 2022

by Grace Wang Jul 14, 2022

In the first half of 2022, China National Medical Products Administration (NMPA) approved 210 domestically-manufactured generic drugs for marketing authorization.1

Overview of the Top 12 Companies

Yangtze River Pharmaceutical is the biggest winner, owning 14 approved generic drugs, followed by Sichuan Kelun Pharmaceutical and Beite Pharmaceutical with 11 approved generics respectively. The fourth and fifth places are taken by Jiangsu Hengrui Pharmaceutical with 9 generic products and CSPC Pharmaceutical with 8 generics.

Ranking

Company

Approved Generic Drugs

Approved Generic Drug Applications

1

Yangtze River Pharmaceutical

14

18

2

Sichuan Kelun Pharmaceutical

11

18

2

Beite Pharmaceutical

11

15

4

Jiangsu Hengrui Pharmaceuticals

9

12

5

CSPC Pharmaceutical

8

12

6

CR Pharmaceutical

7

7

6

SSY Group

7

7

8

Reyoung Pharmaceutical

6

8

9

Qilu Pharmaceutical

5

7

9

Easton Biopharmaceuticals

5

6

9

Sino Biopharmaceutical

5

5

9

Tianyu Pharm

5

5

  Data source: Menet.com.cn

* Notes: The approved generic applications outnumber the approved drugs. The reason is that for products with the same active ingredient but with different strengths and/or dosage forms, the generic drug products' applications are different.

Among the approved generic drugs made by the top 12 companies, 18 are first generics in China, including 6 drugs by Hengrui Pharmaceuticals, 5 by Kelun Pharmaceutical, 2 by Yangtze River Pharmaceutical, and 1 by Beite Pharmaceutical.

"First generic drug in China" refers to the first generic drug developed by Chinese companies and approved by China NMPA. They can enjoy 12-month market exclusivity as they are the first generics to have successfully challenged the patents of innovator drugs.

Related Article: How Does China's Drug Patent Linkage System Work?

Top 4 Companies' Approved Generics

Top 1: Yangtze River Pharmaceutical

Yangtze River Pharmaceutical was the champion in 2021 with 31 approved drugs and comes in the first again with 14 approved generics in H1 2022.

No.

Approved Generic Drug

Registration Classification

Therapeutic Area

1

Ropivacaine Hydrochloride Injection

Class 4

Nervous system

2

Levofloxacin and Sodium Chloride Injection

Class 4

Systemic anti-infection

3

Magnesium Sulfate, Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution

Class 3

Gastrointestinal system and metabolism

4

Levofloxacin Injection

Class 3

Systemic anti-infection

5

Aripiprazole Orally Disintegrating Tablets

Class 3

Nervous system

6

Nifedipine Controlled-release Tablets

Class 4

Cardiovascular and cerebrovascular system

7

Tedizolid Phosphate for Injection

Class 4

Systemic anti-infection

8

Levetiracetam Tablets

Class 4

Nervous system

9

Olmesartan Medoxomil Tablets

Class 4

Cardiovascular and cerebrovascular system

10

Sugammadex Sodium Injection

Class 4

Musculoskeletal system

11

Sitafloxacin Tablets

Class 4

Systemic anti-infection

12

Rocuronium bromide Injection

Class 4

Musculoskeletal system

13

Levosalbutamol Hydrochloride Nebuliser Solution

Class 3

Respiratory system

14

Bivalirudin for Injection

Class 4

Blood and hematopoietic system

*First generics are highlighted in yellow.

*To learn about drug registration class, please refer to China Chemical Drug Registration Classification.

Top 2: Sichuan Kelun Pharmaceutical

Kelun has 11 generics approved in H1 2022, among which five are first generics.

No.

Drug

Registration  Classification

Therapeutic Area

1

Linagliptin Tablets

Class 4

Gastrointestinal system and metabolism

2

Trelagliptin Succinate Tablets

Class 3

Gastrointestinal system and metabolism

3

Medium and Long Chain Fat Emulsion / Amino Acids (16) / Glucose (36%) Injection

Class 3

Blood and hematopoietic system

4

Medium and Long Chain Fat Emulsion / Amino Acids (16) / Glucose (30%) Injection

Class 3

Blood and hematopoietic system

5

Tirofiban Hydrochloride and Sodium Chloride Injection

Class 3

Blood and hematopoietic system

6

Sildenafil Citrate Orodispersible Tablets

Class 4

Reproductive & urinary systems and sex hormones

7

Sugammadex Sodium Injection

Class 4

Musculoskeletal system

8

Ipratropium   Bromide Solution for Inhalation

Class 4

Respiratory system

9

Gadoteridol Injection

Class 4

Others

10

     Linezolid and Glucose Injection

Class 4

Systemic anti-infection

11

Palonosetron Hydrochloride Injection

Class 4

Gastrointestinal system and metabolism

*First generics are highlighted in yellow.

Top 3: Beite Pharmaceutical

Beite also has 11 generic drugs approved in H1 2022, most of which are for anti-infection and the respiratory system.

No.

Drug

Registration   Classification

Therapeutic Area

1

Terbutaline Sulfate Nebuliser Inhalation

Class 4

Respiratory system

2

Levosalbutamol Hydrochloride Nebuliser Solution

Class 3

Respiratory system

3

Pramipexole Dihydrochloride Sustained-release Tablets

Class 4

Nervous system

4

Salbutamol Sulfate Injection

Class 3

Respiratory system

5

Oseltamivir Phosphate for Oral Suspension

Class 4

Systemic anti-infection

6

Oseltamivir Phosphate Capsules

Class 4

Systemic anti-infection

7

Voriconazole for Injection

Class 4

Systemic anti-infection

8

Tranexamic Acid Injection

Class 4

Blood and hematopoietic system

9

Voriconazole Tablets

Class 4

Systemic anti-infection

10

Cefuroxime Axetil for Suspension

Class 3

Systemic anti-infection

11

Benzbromarone Tablets

Class 3

Musculoskeletal system

*First generics are highlighted in yellow.

Top 4: Jiangsu Hengrui Pharmaceuticals

Though Hengrui is not among the top 3 generic approval winners, the company has the highest number of 6 approved first generics in H1 2022.

At the end of 2018, China started mandating that generic drugs must pass the quality and therapeutic equivalence evaluation before applying for joining the volume-based procurement. Since then, Hengrui has shifted its focus to innovator drugs and high-end generic drugs.

No.

Drug

Registration Classification

Therapeutic Area

1

Nimodipine Oral Solution

Class 3

Cardiovascular and cerebrovascular system

2

Paracetamol and Mannitol Injection

Class 3

Nervous system

3

Ondansetron Oral Soluble Pellicles

Class 3

Gastrointestinal system

4

Gadobutrol Injection

Class 4

Other

5

Ambroxol Hydrochloride Oral Solution

Class 3

Respiratory system

6

Omega-3-acid Ethyl Ester 90 Soft Capsules

Class 3

Cardiovascular and cerebrovascular system

8

Medium and Long Chain Fat Emulsion / Amino Acids (16) / Glucose (16%) Injection

Class 4

Blood and hematopoietic system

9

Diquafosol Sodium Eye Drops

Class 4

Sensory system

10

Tacrolimus Sustained-release Capsules

Class 4

Anti-neoplasm and immunomodulation

*First generics are highlighted in yellow.

Related ArticleGeneric Drug Application (ANDA) in China

Related Webinar: Generic Drug Application Procedures in China

Grace Wang
ChemLinked Regulatory Analyst & Editor
+ FOLLOW
Copyright: unless otherwise stated all contents of this website are ©2024 - REACH24H Consulting Group - All Rights Reserved - For permission to use any content on this site, please contact cleditor@chemlinked.com
You May Also Like
Most Popular